Whole-body PBPK model of the dabigatran antidote idarucizumab.
Within this repository, we distribute a whole-body PBPK model of idarucizumab, that has been carefully developed using a large number of clinical studies.
The MoBi project file contains simulations of all published clinical studies employed during model establishment, including the respective observed data digitized from literature reports. For further details, quantitative model evaluation, sensitivity analysis and extensive documentation please refer to [1].
The model is distributed under the GPLv2 License.
[1] Fuhr LM, Hanke N, Meibohm B, Lehr T, Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis, Clin Pharmacokinetics 2020, https://link.springer.com/article/10.1007/s40262-019-00857-y